Declining Currencies Abroad Mean More Competition To India Drug Makers
This article was originally published in PharmAsia News
Increased U.S. competition made possible by the declining value of the dollar is expected to eat into the profit of Indian drug makers this year. Analysts also attribute the profit decline to pricing pressures in the generics sector of the industry. Depreciating currencies also will make competition stronger from other countries as well as the United States, analysts say. Some of the decline is expected to be offset by cheaper raw materials imported to India. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.